Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis.
Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis. Blood Adv. 2026 09 22; 10(18):6188-6197.
PMID: 42341321
ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy.
ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy. Transplant Cell Ther. 2026 Sep 08.
PMID: 42711241
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood Adv. 2026 09 08; 10(17):5778-5788.
PMID: 42085626
CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.
CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study. Lancet Haematol. 2026 Sep; 13(9):e648-e659.
PMID: 42660131
Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy.
Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. Cancer Immunol Res. 2026 Aug 04; 14(8):1292-1306.
PMID: 42112708
Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".
Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia". Haematologica. 2026 Aug 01; 111(8):2873.
PMID: 42609184
Longitudinal patient-reported outcomes and quality-of-life trajectories over 2 years in CAR-T therapy recipients.
Longitudinal patient-reported outcomes and quality-of-life trajectories over 2 years in CAR-T therapy recipients. Blood Neoplasia. 2026 Nov; 3(4):100278.
PMID: 42718878
Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Leukemia. 2026 Oct; 40(10):2181-2190.
PMID: 42469475
CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.
CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study. Cancer Res Commun. 2026 07 01; 6(7):1681-1692.
PMID: 42241689
Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma.
Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e517460.
PMID: 42275618